Author (Year)	Groups Studied and Intervention	Results and Findings	Conclusions
Xu et al., 2019[@146578]	Meta-analysis of safety and tolerability of CGRP mAb, including galcanezumab, erenumab, fremanezumab and eptinezumab	No difference in occurrence of adverse events in eptinezumab 1000mg and placebo in phase II trial. Significantly higher rates of adverse events in galcanexumab 120mg with injection site erythema in 120mg and 240mg. Increased association of nasopharyngitis and pain at injection site with galcanezumab 150mg and 5mg. Higher rates of adverse events with 70mg and 140mg erenumab. Significantly increased treatment-related adverse events with fremanezumab 225mg/month and 675mg/quarter.	Unlink other CGRP mAb, eptinezumab was not associated with increased adverse events or treatment-related adverse events.
Ibekwe et al., 2018[@146610]	Analysis of phase II and III of 4 anti-CGRP monoclonal antibodies: eptinezumab, erenumab, fremanezumab, and galcanezumab	Each showed a statistically significant decrease in frequency of migraines for episodic and chronic migraine sufferers. No safety concerns were identified for any of the four drugs.	Anti-CGRP monoclonal antibody drugs show a strong safety and efficacy profile.
Mitsikostas et al., 2017[@146611]	Literature review of phase 2 CHRP mAbs: eptinezumab, erenumab, galcanezumab, and fremanezumab.	All four drugs show efficacy similar to that of current antimigraine drugs but have promising safety and tolerability profiles.	Larger scale studies are needed to study long term safety and tolerability profiles. Additional evaluation is needed for risk to pregnancy and cardiovascular effects.
Sacco et al., 2019[@146587]	Literature review on use of CGRP monoclonal mAbs.	Quality of evidence for eptinezumab, erenumab, fremanezumab and galcanezumab in treatment of episodic migraine is low to high. Quality of evidence for erenumab, fremanezumab, and galcanezumab for chronic migraine is medium to high.	Monoclonal CGRP mAbs drugs can be recommended for both chronic and episodic migraines. Additional data is needed to improve use of these drugs in clinical practice.